Program
pirtobrutinib
Also written as “Pirtobrutinib”, “LOXO-305” and “[14C]-LOXO-305”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Mantle-Cell · Renal Insufficiency, led by 3 companies.
Drug pagePirtobrutinib: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 2811 open or running | phase 4since Mar 6, 2025 | Nov 6, 2018 | Oct 2027phase 3 · NCT05254743 |
| AstraZenecaits history only | 10 open or running | phase 2since Jan 21, 2025 | Jan 21, 2025 | none ahead |
| Nurix Therapeuticsits history only | 11 open or running | phase 3since Mar 31, 2026 | Mar 31, 2026 | Oct 2029phase 3 · NCT07516093 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 6 earlier studies, Nov 6, 2018 to Aug 24, 2021.
- Jul 28, 2021Named pirtobrutinibINNProposed as its International Nonproprietary Name in WHO's List 125 · before, LOXO-305
- Oct 22, 20212 phase 1 studies in Healthy VolunteersEli Lilly · NCT05134350, NCT05134337
- Jan 3, 2022Phase 1 study in HealthyEli Lilly · NCT05176314 · 32 enrolled · United States
- Feb 15, 2022Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT05254743 · 737 planned · United States, Argentina, Australia and more
- Oct 24, 2023Phase 2 study in Multiple SclerosisEli Lilly · NCT06104683 · United States, Puerto Rico
- Nov 30, 2023Phase 1 study in HealthyEli Lilly · NCT06165146 · 16 enrolled · United States
- Dec 11, 20239 phase 1 studiesEli Lilly · NCT06190691, NCT06190678, NCT06194214 and 6 more
- Feb 6, 2024Phase 1 study in HealthyEli Lilly · NCT06258174 · 28 enrolled · United States
- Sep 6, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06588478 · 249 planned · United States, Australia, Belgium and more
- Dec 3, 2024Phase 2 study in Purpura, Thrombocytopenic, IdiopathicEli Lilly · NCT06721013 · 68 planned · United States, China, Denmark and more
- Jan 21, 2025AstraZeneca’s first study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AstraZenecaAstraZeneca · NCT06839872
- Mar 6, 20252 phase 4 studies in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06876662, NCT06876649
- Aug 29, 2025Phase 2 study in Lymphoma, Non-HodgkinEli Lilly · NCT07162181 · 13 enrolled · China
- Oct 16, 2025Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT07218341 · 150 planned · United States, Australia, Austria and more
- Mar 31, 2026Nurix Therapeutics’ first study: phase 3 study in Lymphoma, B-CellNew to Nurix TherapeuticsNurix Therapeutics · NCT07516093 · 620 planned · United States
Ahead
- Oct 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT05254743
- Nov 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellEli Lilly · NCT04662255
- Feb 2028Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicEli Lilly · NCT06721013
- Jun 2028Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06588478
TargetBeta
“An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07516093Lymphoma, B-Cell · United States | 3 | Recruiting | Nurix Therapeutics | Oct 2029 | 620 |
| NCT07218341Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 4 | Recruiting | Eli Lilly | May 2030 | 150 |
| NCT07162181Lymphoma, Non-Hodgkin · China | 2 | Active, not recruiting | Eli Lilly | May 2030 | 13 |
| NCT06876662Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 4 | Recruiting | Eli Lilly | May 2030 | 279 |
| NCT06876649Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 4 | Recruiting | Eli Lilly | May 2030 | 787 |
| NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell | 2 | Withdrawn | AstraZeneca | Jul 28, 2028 | 0 |
| NCT06721013Purpura, Thrombocytopenic, Idiopathic · United States, China, Denmark and more | 2 | Recruiting | Eli Lilly | Feb 2028 | 68 |
| NCT06588478Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | Jun 2028 | 249 |
| NCT06258174Healthy · United States | 1 | Completed | Eli Lilly | Dec 22, 2021 | 28 |
| NCT06215521Healthy · United States | 1 | Completed | Eli Lilly | Mar 31, 2021 | 31 |
| NCT06215430Healthy · United States | 1 | Completed | Eli Lilly | Apr 15, 2021 | 16 |
| NCT06194214Healthy · United States | 1 | Completed | Eli Lilly | Jun 9, 2021 | 16 |
| NCT06181006Healthy · United States | 1 | Completed | Eli Lilly | Dec 1, 2020 | 24 |
| NCT06180980Healthy · United States | 1 | Completed | Eli Lilly | Mar 8, 2021 | 20 |
| NCT06180967Healthy · United States | 1 | Completed | Eli Lilly | Oct 20, 2020 | 15 |
| NCT06180954Healthy · United States | 1 | Completed | Eli Lilly | Nov 6, 2020 | 9 |
| NCT06190691Hepatic Insufficiency · United States | 1 | Completed | Eli Lilly | Dec 30, 2021 | 36 |
| NCT06190678Renal Insufficiency · United States | 1 | Completed | Eli Lilly | Jun 4, 2021 | 16 |
| NCT06165146Healthy · United States | 1 | Completed | Eli Lilly | Dec 30, 2020 | 16 |
| NCT06104683Multiple Sclerosis · United States, Puerto Rico | 2 | Withdrawn | Eli Lilly | Jan 16, 2026 | 0 |
| NCT05254743Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Oct 2027 | 737 |
| NCT05176314Healthy · United States | 1 | Completed | Eli Lilly | Apr 20, 2022 | 32 |
| NCT05134350Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Mar 23, 2020 | 10 |
| NCT05134337Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Oct 30, 2020 | 27 |
| NCT05023980Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Eli Lilly | Jul 11, 2025 | 282 |
| NCT04965493Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Active, not recruiting | Eli Lilly | Oct 2026 | 600 |
| NCT04849416Leukemia, Lymphoid · China | 2 | Completed | Eli Lilly | Apr 10, 2023 | 87 |
| NCT04666038Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Eli Lilly | Aug 29, 2023 | 238 |
| NCT04662255Lymphoma, Mantle-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Eli Lilly | Nov 2027 | 500 |
| NCT03740529Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 2 | Completed | Eli Lilly | Jan 27, 2025 | 803 |
How it is read
Names in the registry
- “Pirtobrutinib”, 26 entries
- “LOXO-305”, 3 entries
- “[14C]-LOXO-305”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 11 studies
- Lymphoma, B-Cell, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Lymphoma, Mantle-Cell, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.